Literature DB >> 12643160

Blood pressure control--effects on diabetic nephropathy progression: how low does blood pressure have to be?

Christopher A Newton1, Philip Raskin.   

Abstract

Hypertension and diabetes are independent risk factors for both cardiovascular disease and renal complications. Coexistence of these comorbid conditions predisposes the patient to a much greater risk of progression to end-stage renal disease. Combined with the increased cardiovascular mortality, this has led to recent Joint National Committee-VI recommendations for the initiation of antihypertensive therapy for people with diabetes at a blood pressure of 130/85 mm Hg, a level lower than that recommended for the nondiabetic population. Results of a review of recently published investigations on the effects of blood pressure on diabetic nephropathy progression are presented in this article. This review finds evidence to support reducing the mean arterial blood pressure to levels below 95 mm Hg, a level that is even lower than the blood pressure of 130/80 mm Hg (mean arterial pressure of 97 mm Hg) recommended by the American Diabetes Association and National Kidney Foundation. The effect of blood pressure on renal disease progression is linear and appears to have no lower threshold for the benefits of blood pressure reduction on limiting nephropathy progression. The answer to the question of how low does blood pressure have to be to minimize the effects of blood pressure on diabetic nephropathy progression might be "the lower, the better."

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12643160     DOI: 10.1007/s11892-002-0124-0

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  60 in total

1.  Prevalence and management of hypertension in type 1 diabetes mellitus in Europe: the EURODIAB IDDM Complications Study.

Authors:  F Collado-Mesa; H M Colhoun; L K Stevens; J Boavida; J B Ferriss; B Karamanos; P Kempler; G Michel; G Roglic; J H Fuller
Journal:  Diabet Med       Date:  1999-01       Impact factor: 4.359

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

3.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Authors:  H H Parving; H Lehnert; J Bröchner-Mortensen; R Gomis; S Andersen; P Arner
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

4.  Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?

Authors:  G L Bakris; M R Weir
Journal:  Arch Intern Med       Date:  2000-03-13

Review 5.  Are angiotensin-converting enzyme inhibitors the best treatment for hypertension in type 2 diabetes?

Authors:  R Komers; S Anderson
Journal:  Curr Opin Nephrol Hypertens       Date:  2000-03       Impact factor: 2.894

6.  Does ACE inhibition slow progression of glomerulopathy in patients with Type 2 diabetes mellitus?

Authors:  K E White; N Pinel; D J Cordonnier; R W Bilous
Journal:  Diabet Med       Date:  2001-11       Impact factor: 4.359

7.  Treatment of isolated systolic hypertension in the elderly: further evidence from the systolic hypertension in Europe (Syst-Eur) trial.

Authors:  J A Staessen; L Thijs; J Gasowski; H Cells; R H Fagard
Journal:  Am J Cardiol       Date:  1998-11-12       Impact factor: 2.778

Review 8.  Hypertension-related renal injury: a major contributor to end-stage renal disease.

Authors:  W G Walker
Journal:  Am J Kidney Dis       Date:  1993-07       Impact factor: 8.860

9.  Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy. Results of a 2-year prospective, randomized study.

Authors:  L D Elving; J F Wetzels; H J van Lier; E de Nobel; J H Berden
Journal:  Diabetologia       Date:  1994-06       Impact factor: 10.122

10.  Geographical variations in blood pressure in British men and women.

Authors:  N G Bruce; D G Cook; A G Shaper; A G Thomson
Journal:  J Clin Epidemiol       Date:  1990       Impact factor: 6.437

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.